1-4 of 4
Bryson Pottinger
Close
Sort by
Journal Articles

Time Limited Exposure to a ROR1 Targeting Bispecific T Cell Engager (NVG-111) Leads to Durable Responses in Subjects with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

William Townsend, Sarah Leong, Mittal Shah, Toby Batten, David Tucker, Bryson Pottinger, Shankaranarayana Paneesha, Dima El-Sharkawi, Toby A. Eyre, Ho Pui Jeff Lam, Jiexin Zheng, Sarah Cook, David Granger, David Ahern, Kieran O'Donovan, Amit C. Nathwani, Parag Jasani
Journal: Blood
Blood (2023) 142 (Supplement 1): 329.
https://doi.org/10.1182/blood-2023-188607
Published: 2023
Journal Articles

First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)

William Townsend, Sarah Leong, David Tucker, Bryson Pottinger, Shankara Paneesha, Dima El-Sharkawi, Toby A. Eyre, Toby Batten, Mittal Shah, Sarah Cook, David Granger, Kieran O'Donovan, Amit C. Nathwani, Parag Jasani
Journal: Blood
Blood (2022) 140 (Supplement 1): 4162–4163.
https://doi.org/10.1182/blood-2022-169658
Published: 2022
Journal Articles

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Marlijn Hoeks, MD, Tim Bagguley, MS, Rian Roelofs, Msc, Louise De Swart, MD, David Bowen, MD PhD, Argiris Symeonidis, MD PhD, Corine van Marrewijk, PhD, Eva Hellström-Lindberg, MD PhD, Aurelia Tatic, MD, Saskia Langemeijer, MD PhD, Dominic J. Culligan, Marian Macheta, MD, Hege Garelius, MD, Michail Spanoudakis, MD, Sally Killick, MD, Panagiotis Panagiotidis, MD PhD, Oana Stanca Ciocan, MD, Juliet Mills, MD, Bryson Pottinger, Sam Ackroyd, MD, Claire Hall, MD, Jackie Droste, PhD, Alexandra Smith, PhD, Dorine W. Swinkels, MD PhD, Theo M de Witte, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4392.
https://doi.org/10.1182/blood-2018-99-118070
Published: 2018
Journal Articles

A Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma (AITL), an NCRI Clinical Trial. CRUK C17050/A5671

William M Townsend, MRCP, Roderick J. Johnson, MD, Nicholas Counsell, Humra Shah, Bryson Pottinger, Katy Evans, Caroline Wickham, Paul Smith, Rudin Claudius, MD FRCP FRCPath
Journal: Blood
Blood (2012) 120 (21): 3642.
https://doi.org/10.1182/blood.V120.21.3642.3642
Published: 2012